Literature DB >> 21703198

Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C.

Hans L Tillmann1, Keyur Patel, Andrew J Muir, Cynthia D Guy, Josephine H Li, Xiang Qian Lao, Alexander Thompson, Paul J Clark, Stephen D Gardner, John G McHutchison, Jeanette J McCarthy.   

Abstract

BACKGROUND & AIMS: IL28B polymorphisms have been associated with both treatment induced and spontaneous clearance of hepatitis C virus (HCV). We previously found that LDL cholesterol levels were higher in chronic hepatitis C (CHC) patients with the CC genotype at the rs12979860 polymorphism, located proximal to the IL28 gene. Here we analyzed the association of steatosis with IL28B genotype in treatment naïve patients with CHC.
METHODS: Two independent cohorts of 145 genotype 1 infected patients from an antifibrotic study and 180 genotype 1 patients from Duke were analyzed for the presence and severity of steatosis in relation to the rs12979860 polymorphism at the IL28B locus. TaqMan assay based genotyping classified three groups CC, CT, and TT.
RESULTS: CC genotype was associated with a lower prevalence of steatosis. In the antifibrotic study, steatosis was found in 47.6% (50/105) of IL28B non-CC vs. 22.5% (9/40; p=0.008) in CC patients. Similarly, steatosis was found in 67.4% (89/132) of non-CC patients compared to only 39.6% (19/48; p=0.001) of CC patients in the Duke cohort.
CONCLUSIONS: IL28B CC genotype is associated with less pronounced disturbances of lipid metabolism, as reflected both in serum lipoprotein levels and hepatic steatosis, in HCV infection.
Copyright © 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21703198      PMCID: PMC3763913          DOI: 10.1016/j.jhep.2011.03.015

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  22 in total

1.  The effect of interferon on the metabolism of LDLs.

Authors:  G Schectman; S Kaul; R A Mueller; E C Borden; A H Kissebah
Journal:  Arterioscler Thromb       Date:  1992-09

2.  Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C.

Authors:  E Shinohara; S Yamashita; S Kihara; K Hirano; M Ishigami; T Arai; S Nozaki; K Kameda-Takemura; S Kawata; Y Matsuzawa
Journal:  Hepatology       Date:  1997-06       Impact factor: 17.425

3.  Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.

Authors:  David R Nelson; Yves Benhamou; Wan-Long Chuang; Eric J Lawitz; Maribel Rodriguez-Torres; Robert Flisiak; Jens W F Rasenack; Wiesław Kryczka; Chuan-Mo Lee; Vincent G Bain; Stephen Pianko; Keyur Patel; Patrick W Cronin; Erik Pulkstenis; G Mani Subramanian; John G McHutchison
Journal:  Gastroenterology       Date:  2010-07-01       Impact factor: 22.682

4.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

Review 5.  IL28B and the control of hepatitis C virus infection.

Authors:  Ashwin Balagopal; David L Thomas; Chloe L Thio
Journal:  Gastroenterology       Date:  2010-10-13       Impact factor: 22.682

6.  A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice.

Authors:  Hans L Tillmann; Alex J Thompson; Keyur Patel; Manfred Wiese; Hannelore Tenckhoff; Hans D Nischalke; Yuliya Lokhnygina; Ulrike Kullig; Uwe Göbel; Emanuela Capka; Johannes Wiegand; Ingolf Schiefke; Wolfgang Güthoff; Kurt Grüngreiff; Ingrid König; Ulrich Spengler; Jeanette McCarthy; Kevin V Shianna; David B Goldstein; John G McHutchison; Jörg Timm; Jacob Nattermann
Journal:  Gastroenterology       Date:  2010-07-14       Impact factor: 22.682

7.  Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection.

Authors:  John McHutchison; Zachary Goodman; Keyur Patel; Hala Makhlouf; Maribel Rodriguez-Torres; Mitchell Shiffman; Don Rockey; Petr Husa; Wan-Long Chuang; Robert Levine; Mark Jonas; Dickens Theodore; Richard Brigandi; Alison Webster; Margaret Schultz; Helen Watson; Britt Stancil; Stephen Gardner
Journal:  Gastroenterology       Date:  2010-02-13       Impact factor: 22.682

8.  Effect of interferon on plasma lipoproteins and on the activity of postheparin plasma lipases.

Authors:  C Ehnholm; K Aho; J K Huttunen; E Kostiainen; K Mattila; J Pakkarainen; K Cantell
Journal:  Arteriosclerosis       Date:  1982 Jan-Feb

9.  A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis.

Authors:  Masayuki Kurosaki; Kotaro Matsunaga; Itsuko Hirayama; Tomohiro Tanaka; Mitsuaki Sato; Yutaka Yasui; Nobuharu Tamaki; Takanori Hosokawa; Ken Ueda; Kaoru Tsuchiya; Hiroyuki Nakanishi; Hiroki Ikeda; Jun Itakura; Yuka Takahashi; Yasuhiro Asahina; Megumu Higaki; Nobuyuki Enomoto; Namiki Izumi
Journal:  Hepatol Res       Date:  2010-01-11       Impact factor: 4.288

10.  Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group.

Authors:  J H Lefkowitch; E R Schiff; G L Davis; R P Perrillo; K Lindsay; H C Bodenheimer; L A Balart; T J Ortego; J Payne; J L Dienstag
Journal:  Gastroenterology       Date:  1993-02       Impact factor: 22.682

View more
  41 in total

1.  Understanding the role of PNPLA3 genetic variants in patients with chronic hepatitis C infection.

Authors:  Alessio Aghemo
Journal:  Dig Dis Sci       Date:  2012-06-27       Impact factor: 3.199

Review 2.  Genetics of IL28B and HCV--response to infection and treatment.

Authors:  C Nelson Hayes; Michio Imamura; Hiroshi Aikata; Kazuaki Chayama
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-29       Impact factor: 46.802

Review 3.  Genetic background in nonalcoholic fatty liver disease: A comprehensive review.

Authors:  Fabio Salvatore Macaluso; Marcello Maida; Salvatore Petta
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

4.  The MURDOCK Study: a long-term initiative for disease reclassification through advanced biomarker discovery and integration with electronic health records.

Authors:  Jessica D Tenenbaum; Victoria Christian; Melissa A Cornish; Rowena J Dolor; Ashley A Dunham; Geoffrey S Ginsburg; Virginia B Kraus; John G McHutchison; Meredith L Nahm; L Kristin Newby; Laura P Svetkey; Krishna Udayakumar; Robert M Califf
Journal:  Am J Transl Res       Date:  2012-07-23       Impact factor: 4.060

Review 5.  Genotype 3 Infection: The Last Stand of Hepatitis C Virus.

Authors:  Austin Chan; Keyur Patel; Susanna Naggie
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

Review 6.  Significance of genetic polymorphisms in patients with nonalcoholic fatty liver disease.

Authors:  Hisamitsu Miyaaki; Kazuhiko Nakao
Journal:  Clin J Gastroenterol       Date:  2017-03-13

7.  Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.

Authors:  A J Muir; L Gong; S G Johnson; M T M Lee; M S Williams; T E Klein; K E Caudle; D R Nelson
Journal:  Clin Pharmacol Ther       Date:  2013-10-04       Impact factor: 6.875

8.  IL28B rs12979860 is not associated with histologic features of NAFLD in a cohort of Caucasian North American patients.

Authors:  Melanie E Garrett; Manal F Abdelmalek; Allison Ashley-Koch; Michael A Hauser; Cynthia A Moylan; Herbert Pang; Anna Mae Diehl; Hans L Tillmann
Journal:  J Hepatol       Date:  2012-10-11       Impact factor: 25.083

9.  Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis.

Authors:  Mazen Noureddin; Elizabeth C Wright; Harvey J Alter; Shauna Clark; Emmanuel Thomas; Richard Chen; Xiongce Zhao; Cathy Conry-Cantilena; David E Kleiner; T Jake Liang; Marc G Ghany
Journal:  Hepatology       Date:  2013-09-30       Impact factor: 17.425

Review 10.  Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes.

Authors:  Tracey G Simon; Adeel A Butt
Journal:  World J Gastroenterol       Date:  2015-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.